Academic Journal
Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate-to-Severe Atopic Dermatitis.
| Τίτλος: | Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate-to-Severe Atopic Dermatitis. |
|---|---|
| Συγγραφείς: | Kim M; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Del Duca E; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Correa Da Rosa J; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Pulsinelli J; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Estrada Y; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Xu D; Pfizer Inc., San Diego, California, USA., Chan G; Pfizer Inc., Groton, Connecticut, USA., Chen A; Pfizer Inc., Groton, Connecticut, USA., Güler E; Pfizer Inc., Istanbul, Turkey., Page K; Pfizer Inc., Cambridge, Massachusetts, USA., Guttman-Yassky E; Icahn School of Medicine at Mount Sinai, New York, New York, USA. |
| Πηγή: | Allergy [Allergy] 2026 Oct; Vol. 81 (10), pp. 3599-3607. Date of Electronic Publication: 2026 Aug 02. |
| Τύπος έκδοσης: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1398-9995 (Electronic) Linking ISSN: 01054538 NLM ISO Abbreviation: Allergy Subsets: MEDLINE |
| Imprint Name(s): | Publication: Copenhagen : Wiley-Blackwell Original Publication: Copenhagen, Munksgaard. |
| Ιατρικοί όροι (MeSH): | Dermatitis, Atopic*/drug therapy , Dermatitis, Atopic*/diagnosis , Dermatitis, Atopic*/microbiology , Dermatitis, Atopic*/etiology , Microbiota*/drug effects , Pyrimidines*/therapeutic use , Pyrimidines*/pharmacology , Pyrimidines*/administration & dosage , Skin*/microbiology , Skin Microbiome*/drug effects, Adult ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Biomarkers ; Severity of Illness Index ; Treatment Outcome ; Sulfonamides |
| Περίληψη: | Background: Atopic dermatitis (AD) is characterized by microbial dysbiosis, notably an overabundance of Staphylococcus species. This study aimed to evaluate the effects of abrocitinib, a Janus kinase 1-selective inhibitor, on the skin microbiome and clinical outcomes in patients with moderate-to-severe AD. Methods: Patients enrolled in JADE MOA (NCT03915496) were randomly assigned to receive once-daily abrocitinib (100 or 200 mg) or placebo for 12 weeks. Skin swabs collected at baseline and Weeks 2, 4, and 12 underwent 16S rRNA gene amplicon sequencing to determine microbial composition. Disease severity was assessed at the same time points using established clinical metrics. Associations between microbial abundance and clinical metrics, as well as inflammatory and skin barrier markers, were investigated. Results: Data from 43 patients were included. Alpha diversity increased significantly at Week 12 of treatment with abrocitinib 200 mg. Beta diversity analysis revealed clustering of the abrocitinib groups away from placebo as early as Week 2; divergence continued through Week 12. Staphylococcus and S. aureus relative abundance decreased in a dose-dependent manner from Week 2 through Week 12 of abrocitinib treatment. Changes in skin microbial composition corresponded with improvements in clinical metrics of disease severity as well as immune markers of AD. Conclusions: Abrocitinib treatment is associated with beneficial changes in the skin microbiome, notably a reduction in S. aureus and increased microbial diversity. These findings provide insight into the mechanism of action of abrocitinib and the interplay of immunomodulation and the skin microbiome in AD. Trial Registration: ClinicalTrials.gov identifier: NCT03915496. (© 2026 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.) |
| References: | F1000Res. 2016 Jun 24;5:1492. (PMID: 27508062) J Am Acad Dermatol. 2013 Jul;69(1):143-55. (PMID: 23489584) Nat Methods. 2016 Jul;13(7):581-3. (PMID: 27214047) Genome Biol. 2014;15(12):550. (PMID: 25516281) J Eur Acad Dermatol Venereol. 2023 Jun;37 Suppl 5:3-17. (PMID: 37232427) Br J Dermatol. 2010 Sep;163(3):659-61. (PMID: 20545685) Methods Mol Biol. 2018;1849:143-168. (PMID: 30298253) J Invest Dermatol. 2026 Feb;146(2):483-492.e8. (PMID: 40738245) Allergy. 2023 Aug;78(8):2290-2300. (PMID: 37032440) Genome Res. 2012 May;22(5):850-9. (PMID: 22310478) Pac Symp Biocomput. 2012;:235-46. (PMID: 22174279) Lancet. 2020 Jul 25;396(10246):255-266. (PMID: 32711801) PLoS Comput Biol. 2014 Apr 03;10(4):e1003531. (PMID: 24699258) Nat Rev Dis Primers. 2018 Jun 21;4(1):1. (PMID: 29930242) Semin Cutan Med Surg. 2008 Jun;27(2):144-50. (PMID: 18620136) Nat Rev Microbiol. 2018 Mar;16(3):143-155. (PMID: 29332945) J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2056-2066. (PMID: 37335885) J Allergy Clin Immunol. 2023 Nov;152(5):1179-1195. (PMID: 37315812) Appl Environ Microbiol. 2006 Jul;72(7):5069-72. (PMID: 16820507) J Clin Cell Immunol. 2011 Aug 10;2(3):. (PMID: 21994899) J Am Acad Dermatol. 2023 Apr;88(4):816-823. (PMID: 36473633) Allergy Asthma Immunol Res. 2019 Sep;11(5):593-603. (PMID: 31332972) J Allergy Clin Immunol. 2019 Jan;143(1):155-172. (PMID: 30194992) Microorganisms. 2021 Jul 13;9(7):. (PMID: 34361924) J Allergy Clin Immunol. 2010 Dec;126(6):1184-90.e3. (PMID: 21036388) J Invest Dermatol. 2020 Jan;140(1):191-202.e7. (PMID: 31252032) Int J Mol Sci. 2023 Aug 30;24(17):. (PMID: 37686269) Allergy Asthma Immunol Res. 2021 Sep;13(5):762-775. (PMID: 34486260) Nat Biotechnol. 2019 Aug;37(8):852-857. (PMID: 31341288) Nat Med. 2021 Apr;27(4):700-709. (PMID: 33619370) Allergy. 2024 May;79(5):1258-1270. (PMID: 38108208) |
| Grant Information: | Pfizer |
| Contributed Indexing: | Keywords: Staphylococcus aureus; JAK; JAK 1; abrocitinib; atopic dermatitis; inflammation; microbiome |
| Molecular Sequence: | ClinicalTrials.gov NCT03915496 |
| Substance Nomenclature: | 73SM5SF3OR (abrocitinib) 0 (Biomarkers) 0 (Pyrimidines) 0 (Sulfonamides) |
| Entry Date(s): | Date Created: 20260802 Date Completed: 20261008 Latest Revision: 20261016 |
| Update Code: | 20261017 |
| PubMed Central ID: | PMC13646857 |
| DOI: | 10.1111/all.70467 |
| PMID: | 42543003 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1398-9995 |
|---|---|
| DOI: | 10.1111/all.70467 |